RESEARCH-USE BIOSIMILAR ANTIBODY
Donanemab
Monoclonal antibody · IgG1
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research.
TARGETAPP
YMonoclonal antibody
CATALOGSC-BS-616
CATALOG NUMBERSC-BS-616
MOLECULAR WEIGHTApprox. 145.36 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research.
Donanemab is a recombinant research-use antibody directed against APP.